214 related articles for article (PubMed ID: 28818465)
1. Girdin protein expression is associated with poor prognosis in patients with invasive breast cancer.
Choi JS; Kim KH; Oh E; Shin YK; Seo J; Kim SH; Park S; Choi YL
Pathology; 2017 Oct; 49(6):618-626. PubMed ID: 28818465
[TBL] [Abstract][Full Text] [Related]
2. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
[TBL] [Abstract][Full Text] [Related]
3. The impact of Girdin expression on recurrence-free survival in patients with luminal-type breast cancer.
Nishimae K; Tsunoda N; Yokoyama Y; Kokuryo T; Iwakoshi A; Takahashi M; Nagino M
Breast Cancer; 2015 Sep; 22(5):445-51. PubMed ID: 24155038
[TBL] [Abstract][Full Text] [Related]
4. [Expression and significance of phosphorylated Girdin in breast cancer].
Xu Y; Fu L; Gu F; Ma YJ
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):205-9. PubMed ID: 22780975
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer brain metastases at initial diagnosis.
Leone JP; Leone J; Zwenger AO; Iturbe J; Leone BA; Vallejo CT
Eur J Cancer; 2017 Mar; 74():17-25. PubMed ID: 28335884
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of total and tyrosine phosphorylated GIV/Girdin in breast cancers.
Dunkel Y; Diao K; Aznar N; Swanson L; Liu L; Zhu W; Mi XY; Ghosh P
FASEB J; 2016 Nov; 30(11):3702-3713. PubMed ID: 27440794
[TBL] [Abstract][Full Text] [Related]
9. Elevated expression of Girdin in the nucleus indicates worse prognosis for patients with estrogen receptor-positive breast cancer.
Peng WT; Hu X; Yao L; Jiang YZ; Shao ZM
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S648-56. PubMed ID: 24793340
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
11. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
Choi JE; Kang SH; Lee SJ; Bae YK
Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
[TBL] [Abstract][Full Text] [Related]
13. Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression.
Schmidt G; Meyberg-Solomayer G; Gerlinger C; Juhasz-Böss I; Herr D; Rody A; Liedtke C; Solomayer EF
Arch Gynecol Obstet; 2014 Dec; 290(6):1221-9. PubMed ID: 25012601
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics and Prognosis of Pregnancy-Associated Breast Cancer: Poor Survival of Luminal B Subtype.
Bae SY; Jung SP; Jung ES; Park SM; Lee SK; Yu JH; Lee JE; Kim SW; Nam SJ
Oncology; 2018; 95(3):163-169. PubMed ID: 29913459
[TBL] [Abstract][Full Text] [Related]
15. Girdin protein: a new potential distant metastasis predictor of breast cancer.
Liu C; Zhang Y; Xu H; Zhang R; Li H; Lu P; Jin F
Med Oncol; 2012 Sep; 29(3):1554-60. PubMed ID: 22116776
[TBL] [Abstract][Full Text] [Related]
16. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer subtype as a predictor for outcomes and control in the setting of brain metastases treated with stereotactic radiosurgery.
Grubb CS; Jani A; Wu CC; Saad S; Qureshi YH; Nanda T; Yaeh A; Rozenblat T; Sisti MB; Bruce JN; McKhann GM; Sheth SA; Lesser J; Cheng SK; Isaacson SR; Lassman AB; Connolly EP; Wang TJ
J Neurooncol; 2016 Mar; 127(1):103-10. PubMed ID: 26615564
[TBL] [Abstract][Full Text] [Related]
18. Outcomes in patients with small node-negative invasive breast cancer.
Bao J; Donovan C; Amersi F; Zhang X; Giuliano AE; Chung A
Breast J; 2019 Jul; 25(4):638-643. PubMed ID: 31079425
[TBL] [Abstract][Full Text] [Related]
19. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
20. Combination of cytoplasmic and nuclear girdin expression is an independent prognosis factor of breast cancer.
Zhang H; Yu F; Qin F; Shao Y; Chong W; Guo Z; Liu X; Fu L; Gu F; Ma Y
FASEB J; 2018 May; 32(5):2395-2410. PubMed ID: 29259035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
